Indication of Xigris:
Xigris is a fibrinolytic agent used for to reduce mortality in adult patients with severe, life threatening sepsis.
Action of Xigris:
Xigris (dogrecogin alfa) is human activated protein C made with recombinant DNA technology, it has similar properties to natural human activated protein C.Activated protein C increases the breakdown of blood clots and has anti-inflammatory activity.90% of the steady state condition is achieved within two hours of commencing an infusion. After the completion of an infusion, activated protein C concentrations exhibit a biphasic half life with a rapid intial phase of 13 minutes, and a slower second phase of 16 hours.The mechanism by which activated protein C is cleared from the plasma is unknown.
Dose Advice of Xigris:
Continuous infusion: 24 microgram/kg/hour, over 96 hours.
Schedule of Xigris:
S4
Common side effects of Xigris:
Bruising.Increased bleeding
Uncommon side effects of Xigris:
Serious bleeding (e.g. intracranial haemorrhage, life threatening bleeding or bleeding requiring transfusion of at least 3 units of packed red cells per day for two days) occurs in about 35% of patients.
Diseases treated by Xigris:
Pulmonary embolism (PE)
